Creative Medical Technology Holdings, Inc. (CELZ) 2025 Annual Report: Key Investor Highlights

Overview

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has released its 2025 Annual Report, providing a comprehensive update on its operations, financial condition, and strategic direction. The company, headquartered in Phoenix, AZ, is a commercial-stage biotechnology firm focused on regenerative therapies in immunotherapy, endocrinology, urology, neurology, and orthopedics.

Key Developments & Financial Performance

• Clinical Trial Progress: CELZ successfully completed patient enrollment in its ADAPT clinical trial for CELZ-201 (Olastrocel) during December 2025. This milestone enables the company to proceed to the next phase of follow-up and data analysis, a crucial step toward potential commercialization.
• New Investments: In November 2025, CELZ contributed \$43,200 to Bionance, a joint venture, which was used alongside additional funds to invest in a convertible note and warrants from Applife Digital Solutions, Inc. This marks CELZ’s ongoing strategy to leverage external opportunities in the biotech sector.
• Capital Raises: The company completed a registered direct offering on October 23, 2024, selling 418,552 shares of common stock at \$4.42 per share and issuing warrants for 837,104 shares at the same exercise price. Net proceeds were approximately \$1.6 million, with Roth Capital Partners acting as placement agent. Further, in March 2025, CELZ entered into warrant exercise inducement agreements on the same warrants, resulting in additional gross proceeds of \$3.7 million.
• Cash Position & Liquidity: As of December 31, 2025, CELZ held approximately \$7.2 million in cash and short-term U.S. treasuries. The company raised over \$40 million in gross proceeds from securities offerings between 2021 and 2025.
• Operating Losses: CELZ reported an operating loss of approximately \$6.1 million for 2025 (and \$5.7 million for 2024). The company expects continued operating losses until it can generate significant revenue from product sales, licensing, or royalties.
• Revenue Generation: Revenue from CaverStem® kits was minimal, at \$6,000 for 2025 and \$11,000 for 2024. The company anticipates increased expenses as it advances clinical trials and expands its research and development efforts.

Intellectual Property & R&D

• CELZ continues to strengthen its intellectual property portfolio, with a robust suite of patents and pending applications, especially in the area of regenerative medicine and stem cell platforms. Research and development expenses for 2024 were \$2,400,777.
• The company is developing an induced pluripotent stem cell (iPSC) line in partnership with Greenstone Biosciences, Inc.

Regulatory and Commercial Risks

• Clinical & Regulatory Risks: CELZ’s product candidates are subject to ongoing preclinical studies, clinical trials, and regulatory approvals. The company faces significant risks typical in the biotech sector, including potential delays, failures in trials, or inability to obtain or maintain required FDA or other regulatory approvals.
• Funding Risks: Despite a strong cash position, management admits that additional capital will be needed to continue R&D, clinical trials, and commercialization efforts. There is no guarantee of securing such funding on favorable terms, which could result in dilution for existing shareholders or a reduction in operational scope.
• Revenue & Profitability: The company has generated minimal revenues and will not achieve profitability unless it can significantly increase sales from products or therapies that are currently not yet commercialized. This uncertainty is a key risk factor for investors.
• Product and Market Risks: Any failure in clinical trials, regulatory setbacks, or inability to secure reimbursement or market access for new therapies could materially and adversely affect the company’s prospects.

Other Noteworthy Information for Shareholders

• Public Float & Outstanding Shares: As of June 30, 2025, the public float was valued at \$4,633,334. As of March 20, 2026, there were 3,696,668 shares of common stock outstanding.
• Corporate Governance: CELZ is a non-accelerated filer and a smaller reporting company, but not an emerging growth company or shell company.
• Forward-Looking Statements: Management emphasizes that all forward-looking statements are subject to significant risks and uncertainties, including but not limited to, the ability to raise capital, successful product development, clinical trial outcomes, regulatory approvals, and competitive pressures.

Potential Price-Sensitive Information

• Clinical Trial Milestones: The completion of enrollment for the ADAPT clinical trial (CELZ-201, Olastrocel) and transition to follow-up/data analysis is a significant milestone. Positive results or further progress could materially impact share price.
• Capital Raises and Use of Proceeds: The company’s ability to raise funds through direct offerings and warrant exercises reflects confidence from institutional investors but also points to continued dilution risk for shareholders.
• Ongoing Losses and Funding Needs: Continued operating losses and the explicit need for further capital raises are critical issues that could impact investor sentiment and share value.

Conclusion

Investors should note that Creative Medical Technology Holdings, Inc. is at a pivotal stage, advancing several promising regenerative therapies. The company’s progress in clinical trials, ability to secure capital, and successful execution of its R&D programs will be key factors influencing future share performance. However, continued operating losses, funding needs, and the risks inherent to biotech development are important considerations for all shareholders.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. The biotechnology sector is subject to high risk and volatility. Forward-looking statements are subject to change based on future events or market conditions. Always consult with a qualified financial advisor.

View CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Historical chart here